Key Takeaways:
- FDA granted priority review to Sanofi's venglustat for type 3 Gaucher disease
- PDUFA decision date set for Nov. 25, 2026
- Drug would be first US therapy targeting neurological symptoms of GD3
Back
Sanofi secures FDA priority review for Gaucher drug venglustat
The US Food and Drug Administration granted priority review to Sanofi's new drug application for venglustat, an oral therapy for type 3 Gaucher disease, setting a Nov. 25 decision date for what would be the first US treatment targeting the condition's neurological symptoms.
"Venglustat has the potential to address a significant unmet need for patients with type 3 Gaucher disease who currently have no approved therapy for the neurological manifestations of this progressive disorder," a Sanofi spokesperson said.
The filing is backed by the Phase III LEAP2MONO trial, which enrolled 43 patients aged 12 and older whose systemic symptoms were already stabilized on enzyme replacement therapy. Venglustat met both primary endpoints at 52 weeks, showing statistically significant improvements on the Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) compared with continued ERT infusions. The drug also hit three of four secondary endpoints, including comparable control of non-CNS symptoms such as spleen and liver volume.
Venglustat is a glucosylceramide synthase inhibitor designed to cross the blood-brain barrier and reduce the buildup of toxic glycosphingolipids in the central nervous system. In Gaucher disease type 3, this accumulation drives neuroinflammation, ataxia, and cognitive decline — symptoms that existing enzyme replacement therapies cannot address because they do not penetrate the brain. The most common adverse events in the venglustat arm were headaches, nausea, spleen enlargement, and diarrhea.
The drug has had a difficult development history. Sanofi once viewed venglustat as a potential blockbuster "pipeline-in-a-pill" with applications across multiple lysosomal storage disorders, but the candidate failed in trials for Fabry disease, Parkinson's disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. The GD3 indication now represents its best path to market.
Sanofi already dominates the Gaucher market with two approved therapies: Cerezyme (imiglucerase), an intravenous ERT that generated peak sales of more than $1 billion annually, and Cerdelga (eliglustat), an oral therapy for type 1 disease. Venglustat would expand that franchise into the neurological segment of type 3 disease, which is the most common form globally but less prevalent in the US and Europe.
The FDA previously granted venglustat breakthrough therapy, fast-track, and orphan drug designations for GD3. The drug is also under regulatory review in the European Union, with additional global filings planned for later this year.
For Sanofi investors, the Nov. 25 PDUFA date is the next catalyst for a rare disease pipeline that has delivered more setbacks than successes in recent years. Sanofi shares have declined 8.6% year to date through May 29, underperforming the broader market. Approval would validate the company's bet on a molecule that has survived multiple clinical failures, though peak sales expectations for the GD3 indication alone are modest relative to the blockbuster forecasts Sanofi once attached to the program.
This article is for informational purposes only and does not constitute investment advice.
